MedicalDevice Licensing.com
Innovaro Pharmalicensing
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register
About Us
Innovaro Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Pay-per-Click New!
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Innovaro Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Innovaro Pharmalicensing
is a division of
Innovaro Europe Ltd
Innovaro Corporation
Industry news

Related news

Latest News

NOVELOS THERAPEUTICS BELIEVES CLASS ACTION LAWSUIT IS WITHOUT MERIT AND INTENDS TO DEFEND VIGOROUSLY
Colon Cancer Alliance and Moffitt Cancer Center Host Interactive Support Program
ExonHit and bioM
FDA Approves Name Change for Heartburn Drug Kapidex
ENANTA NOMINATES EDP-239 AS LEAD DEVELOPMENT CANDIDATE FOR NS5A HCV INHIBITOR PROGRAM
Abbott and Enanta Announce Advancement of Hepatitis C Collaboration
Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122
Light Sciences Oncology Meets a Major Milestone in Aptocine Development with Target Enrollment in Phase 3 MCRC Trial
Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122
enGene, Inc. to Present Research Data on EG-10 for Inflammatory Bowel Disease (IBD)
More news... | RSS Feed...

Most Viewed

Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122

Light Sciences Oncology Meets a Major Milestone in Aptocine Development with Target Enrollment in Phase 3 MCRC Trial

NOVELOS THERAPEUTICS PIVOTAL PHASE 3 LUNG CANCER TRIAL DOES NOT MEET THE PRIMARY SURVIVAL ENDPOINT

NOVELOS THERAPEUTICS BELIEVES CLASS ACTION LAWSUIT IS WITHOUT MERIT AND INTENDS TO DEFEND VIGOROUSLY

ENANTA NOMINATES EDP-239 AS LEAD DEVELOPMENT CANDIDATE FOR NS5A HCV INHIBITOR PROGRAM

enGene, Inc. to Present Research Data on EG-10 for Inflammatory Bowel Disease (IBD)

Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet primary endpoint

Colon Cancer Alliance and Moffitt Cancer Center Host Interactive Support Program

Abbott and Enanta Announce Advancement of Hepatitis C Collaboration

Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint

Therapeutic Target

Cardiovascular
Dermatology
Endocrine and Metabolic
Gastroenterology
Genitourinary
Hematology
Immunology and Allergy
Infection
Musculoskeletal
Neurology
Obstetrics and Gynecology
Oncology
Ophthalmology
Psychiatry
Pulmonary

Categories

Deals and Alliances
Development
Financial Results
Financings
Intellectual Property
Regulatory
Press releases
Deals review
Headlines
PR Newswire

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Pharma Partnering Live
Press releases: Innovaro Pharmalicensing current industry press releases.

© Copyright 1998-2010 Innovaro Pharmalicensing, a division of Innovaro Europe Ltd Innovaro Corporation All rights reserved. Terms and Conditions | Contact us